0000000000896730

AUTHOR

Inga Stukena

showing 3 related works from this author

PAI-1 Level Differences in Malignant Plural Effusion, Parapneumonic Pleuritis, and Cardiac Hydrothorax

2019

Background and Objectives: Plasminogen activator inhibitor-1 (PAI-1) is a fibrinolytic system enzyme whose role in various fibrinolytic processes is currently unknown. In clinical manifestations of pleural liquids of diverse etiology, various levels of fibrinolytic activity can be observed&mdash

AdultMalemedicine.medical_specialtypleural effusion; malignant pleural effusion; plasminogen activator inhibitor-1Pleural effusionHydrothoraxGastroenterologyFibrinArticlechemistry.chemical_compoundpleural effusionInternal medicinemedicine.arteryPlasminogen Activator Inhibitor 1medicineMalignant pleural effusionHumansmalignant pleural effusionPleurisyAgedAged 80 and overlcsh:R5-920biologybusiness.industryGeneral MedicineMiddle Agedmedicine.diseaseLatviaPleural Effusion MalignantchemistryEffusionPlasminogen activator inhibitor-1Pulmonary arterybiology.proteinHydrothoraxEtiologyplasminogen activator inhibitor-1Femalelcsh:Medicine (General)businessMedicina
researchProduct

Relation of inflammatory chemokines to insulin resistance and hypoadiponectinemia in coronary artery disease patients

2009

Although many studies have shown that the metabolic syndrome (MS) and type 2 diabetes mellitus (T2DM) both are associated with chronic inflammatory state and are risk factors for coronary artery disease (CAD), it is still unclear which condition is a more important contributor to the increased production of inflammatory chemokines. The purpose of this study was to assess monocyte chemoattractant protein-1 (MCP-1) and interleukin-8 (IL-8) levels and their association with insulin resistance and adiponectin concentrations in CAD patients, who were categorized as having T2DM, MS, or neither.CAD male patients were categorized into three groups: 24 non-obese patients with T2DM (D), 24 obese pati…

AdultMalemedicine.medical_specialtyChemokineDecreased adiponectinCoronary Artery DiseaseCoronary artery diseaseInsulin resistanceRisk FactorsInternal medicineInternal MedicinemedicineHumansObesityChemokine CCL2AgedMetabolic SyndromeAdiponectinbiologybusiness.industryMonocyteInterleukin-8nutritional and metabolic diseasesType 2 Diabetes MellitusMiddle Agedmedicine.diseasemedicine.anatomical_structureEndocrinologyDiabetes Mellitus Type 2biology.proteinAdiponectinInsulin ResistanceMetabolic syndromebusinessBiomarkersEuropean Journal of Internal Medicine
researchProduct

Blood pressure control in treated hypertensive patients in daily practice of Latvian family physicians.

2011

Background and Objective. The aim of this study was to evaluate blood pressure (BP) control level in treated hypertensive patients in Latvia and to compare their characteristics according to the adequacy of BP control. Materials and Methods. Family physicians collected information on demographic and clinical characteristics, and current antihypertensive treatment of 455 18–80-year-old patients with essential arterial hypertension treated for 1 or more years. Target BP was defined as values of <140/90 mm Hg for patients with low or moderate cardiovascular risk and <135/85–125/75 mm Hg for patients with high or very high risk. BP was measured in the office setting after a 5-minute rest …

Blood pressure controlAdultMalemedicine.medical_specialtyAdolescentBlood Pressurearterial hypertension; blood pressure control; antihypertensive drugsSittingYoung AdultRisk groupsInternal medicineDaily practicemedicineAneroid sphygmomanometerHumansIn patientAntihypertensive AgentsAgedAged 80 and overControl levelbusiness.industryPhysicians FamilyBlood Pressure DeterminationGeneral MedicineMiddle AgedLatviaBlood pressureTreatment OutcomeHypertensionPhysical therapyFemalebusinessMedicina (Kaunas, Lithuania)
researchProduct